2020
Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure
Akdemir K, Le V, Kim J, Killcoyne S, King D, Lin Y, Tian Y, Inoue A, Amin S, Robinson F, Nimmakayalu M, Herrera R, Lynn E, Chan K, Seth S, Klimczak L, Gerstung M, Gordenin D, O’Brien J, Li L, Deribe Y, Verhaak R, Campbell P, Fitzgerald R, Morrison A, Dixon J, Andrew Futreal P. Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure. Nature Genetics 2020, 52: 1178-1188. PMID: 33020667, PMCID: PMC8350746, DOI: 10.1038/s41588-020-0708-0.Peer-Reviewed Original ResearchConceptsCancer genomesMutational processesGenome organizationThree-dimensional genome organizationThree-dimensional chromatin structureSomatic mutationsSpatial genome organizationMutation rate variationDifferent human cancer typesDifferent mutational processesWhole-genome datasetsActive mutational processesSpecific mutational processesChromatin structureHuman cancer typesMutation distributionInactive domainsDevelopment of cancerDriver genesGenomeMutational loadActive domainHuman cancersMutationsNovel therapeutic strategies
2012
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells
Tian Z, Zhao J, Tai Y, Amin S, Hu Y, Berger A, Richardson P, Chauhan D, Anderson K. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood 2012, 120: 3958-3967. PMID: 22983447, PMCID: PMC3496955, DOI: 10.1182/blood-2012-01-401794.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBoron CompoundsCell DeathCell Line, TumorCell MovementCell SurvivalCluster AnalysisDrug Resistance, NeoplasmGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, Tumor SuppressorGlycineHumansImidazolesMiceMicroRNAsMultiple MyelomaProto-Oncogene Proteins c-pim-1PyridazinesSignal TransductionXenograft Model Antitumor AssaysConceptsMultiple myelomaMM cellsPim-1Tumor suppressor geneTranscriptional regulationPim-1 overexpressionBiochemical inhibitorsApoptotic signalingRole of miRTumor suppressorMiR33bMM cell viabilityCell deathPatient MM cellsMM xenograft modelNovel therapeutic strategiesLuciferase activityColony formationOverexpressionMiR profilingTumor pathogenesisInvestigational agentsCritical roleRegulationCell viability